Tier 1 — highest

Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects

Elke Theuwissen, Ellen C Cranenburg, Marjo H Knapen, Elke J Magdeleyns, Kirsten J Teunissen, Leon J Schurgers, Egbert Smit, Cees Vermeer
The British journal of nutrition 2012 108(9):1652-7

Bibliography

PubMed
PMID 22289649
DOI
10.1017/S0007114511007185
Funding
Funding is not specified in the indexed abstract or accessible funding metadata. Consult the original publication for the declaration.
Competing interests
A competing-interest declaration is not available in the indexed abstract or accessible disclosure metadata.

Study snapshot

DesignRandomized controlled clinical trial
ModelHuman participants
Sample42 healthy adults aged 18–45
InterventionMK-7 10–360 μg/day or placebo
DurationDose-response intervention; see source for full schedule
EndpointsOsteocalcin and matrix Gla-protein carboxylation; Thrombin generation

What the study showed, in plain terms

This publication examines osteocalcin and matrix gla-protein carboxylation, thrombin generation. Study population or evidence base: 42 healthy adults aged 18–45. Intervention or exposure: MK-7 10–360 μg/day or placebo.

Key findings

Nutritional MK-7 doses improved extra-hepatic vitamin K biomarkers without increasing measured thrombin-generation potential in healthy volunteers.

What this study can and cannot tell us

Small dose groups were pooled for analysis. Findings in healthy volunteers do not establish safety for people taking vitamin K antagonists.

Related papers in the corpus

Tier 1
Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women
M H J Knapen et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013
Tier 1
The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial
S H Rønn et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
Tier 1
Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women
Sofie Hertz Rønn et al. · European journal of endocrinology · 2016
Tier 1
Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial
N Emaus et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010
Tier 1
Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study
Yingfeng Zhang et al. · Calcified tissue international · 2020
Tier 1
Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women
M H J Knapen et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research